Targeting MTERF3 induces mitochondrial transcription inhibition, mitochondrial dysfunction and ROS accumulation, activating p38 MAPK pathway and inhibiting HCC cells proliferation, which suggests that MTERF3 may serve as a promising biomarker used for HCC prognosis and targeted treatment. Here, MTERF3 is linked to hepatocellular carcinoma.